BioSpace News Archive

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for first quarter 2021 after the close of trading on Wednesday, May 5, 2021

During its 2021 virtual Annual Meeting, the International Society of Heart and Lung Transplantation honored the recipients of its 2020 and 2021 Lifetime Achievement Awards, and announced the creation of the Amanda W. Rowe Distinguished Service Award.

Medicure Inc., a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, reported that after nearly 10 years with Medicure, Chief Financial Officer James Kinley is resigning, effective May 15, 2021, to pursue another business opportunity.

The California Pharmacists Association has announced the winners of its 2021 Chapter Awards. The awardees will be recognized at a ceremony in Indian Wells, California on June 19, 2021, during Western Pharmacy Exchange.

Canon Medical is bringing the power of accessible artificial intelligence (AI) for improved image quality to more patients with expanded clinical indications for 3T MR

Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the 2021 B. Riley Securities’ Neuroscience Conference.

MedX Health Corp. announced its results for the year ended December 31, 2020, which are also available on SEDAR.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that its first quarter 2021 financial results will be released after the markets close on Wednesday, May 5th

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical study of XmAb564

CorWave, a French medical device company committed to the fight against heart failure, unveiled an unprecedented study on the performance of its implantable heart pump at the 41st Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT).